AtriCure, Inc. - ATRC STOCK NEWS

AtriCure announced the initiation of the HEAL-IST trial, the first patient was treated at University Hospital Brussels. This trial will assess the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp for patients with Inappropriate Sinus Tachycardia, a condition that affects young adults with limited treatment options. The trial will involve 142 patients across 40 centers in the U.S. and Europe, focusing on achieving a heart rate of less than 90 bpm. The study aims to establish a new standard of care for this condition.

AtriCure, Inc. has appointed Deborah Yount as the new Chief Human Resources Officer, effective immediately. Yount joins from Medtronic, where she was Vice President of Global Human Resources for the Cardiovascular sector, significantly impacting over $10 billion in annual revenue. CEO Michael Carrel expressed enthusiasm about Yount's extensive experience in human capital management, anticipating strong growth opportunities in addressing the Afib epidemic and improving post-operative pain management.

AtriCure, Inc. (Nasdaq: ATRC) reported its first quarter 2022 financial results, showcasing a 25.8% revenue increase to $74.6 million compared to Q1 2021. U.S. revenue rose by 23.8% to $62.3 million, driven by strong sales in cryoSPHERE® probes and AtriClip® Flex-V devices. International revenue also surged by 37.2% to $12.3 million. Despite a net loss of $14.2 million, the company maintains a positive outlook with projected full-year revenue of $318 million to $330 million, anticipating 16% to 20% growth for 2022.

AtriCure, Inc. (NASDAQ: ATRC) has launched the EnCompass Clamp^® as part of its Isolator Synergy™ Ablation System in the U.S. The clamp received FDA 510(k) clearance for cardiac tissue ablation during surgery, enhancing efficiency in concomitant ablation procedures. Key features include parallel closure, uniform pressure, and a magnetic guide for easier placement. CEO Michael Carrel highlighted its innovative design to improve surgical outcomes, while Dr. Prem Samuel praised its efficiency in minimizing tissue dissection and achieving effective results in a single maneuver.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its upcoming release of first-quarter financial results on May 3, 2022, at 4:30 PM ET. Investors can join a conference call or access a live audio webcast via the company's website. AtriCure's innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and the widely used AtriClip® Left Atrial Appendage Exclusion System, support efficient Afib treatment, impacting millions globally. For more information, visit AtriCure.com.

AtriCure, Inc. (Nasdaq: ATRC) reported strong financial results for Q4 and full-year 2021. Q4 revenue reached $73.2 million, up 26.8% from 2020, driven by U.S. sales of key products. Full-year revenue was $274.3 million, a 32.8% increase. Gross profit for 2021 was $205.9 million, while the gross margin improved to 75%. However, the company faced a loss from operations of $12.5 million in Q4 and anticipates an adjusted EBITDA loss in 2022. The 2022 revenue forecast ranges from $315 million to $330 million, reflecting growth of 15% to 20%.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. Eastern Time. Interested parties can access the live audio webcast via the company's website. AtriCure offers innovative solutions for Afib, impacting over 33 million people globally. Their FDA-approved Isolator® Synergy™ Ablation System is a key technology, along with the widely used AtriClip® for left atrial appendage management.

AtriCure, a leader in surgical treatments for atrial fibrillation, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. A conference call will follow at 4:30 p.m. ET the same day, accessible via phone or live audio webcast. AtriCure offers innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® products, which are widely used for managing Afib. With over 33 million people affected by Afib globally, AtriCure is committed to improving patient outcomes.